Sam Harirforoosh

Professor

Pharmacy, School of Pharmacy

Expertise: Pharmaceutics; Pharmacokinetic/Pharmacodynamic Modeling; Safety Pharmacology; Pharmacogenomics

Office Location: RK-94 297R

Education:: Tehran University of Medical Sciences, Doctor of Pharmacy
University of Alberta, Ph.D.

Biography

Dr. Sam Harirforoosh joined Chapman University School of Pharmacy (CUSP) as an Instructional Professor of Biomedical and Pharmaceutical Sciences in 2022. He earned his Pharm.D. from Tehran University of Medical Sciences in 1991 and his Ph.D. in Pharmaceutical Sciences (Pharmacokinetics) from the University of Alberta in 2005. He also worked as a research assistant and post-doctoral fellow in the University of Alberta's Department of Medicine from summer 2005 to spring 2006.

At CUSP, he coordinates, co-coordinates, and contributes to multiple courses in pharmacology, pharmaceutics, and drug metabolism for both Pharm.D. candidates and graduate students. In 2023, he received CUSP's Most Outstanding Teacher award for the 2022-2023 academic year, presented by the Class of 2025.

Before joining CUSP, Dr. Harirforoosh was a tenured professor in the Department of Pharmaceutical Sciences at East Tennessee State University's Gatton College of Pharmacy. He coordinated and taught courses in pharmacokinetics, pharmacogenomics, and drug metabolism. He received the Gatton College of Pharmacy Outstanding Teacher Award (presented by the Class of 2017) for his teaching of the “Pharmacokinetics & Pharmacogenomics” course.

Dr. Harirforoosh has authored or co-authored more than 45 peer-reviewed articles and over 80 abstracts. He has served on the editorial boards of the journals Clinical Pharmacokinetics and European Journal of Drug Metabolism and Pharmacokinetics. He has given numerous lectures at local, national, and international conferences, received two research awards from the Gatton College of Pharmacy for his research achievements, and served as an abstract reviewer, grant reviewer, and peer reviewer for various scientific journals. Additionally, he has mentored over 45 Ph.D., Pharm.D., MPH, and undergraduate students as a research adviser.

Dr. Harirforoosh's research interests include applying artificial intelligence tools to pharmacokinetic outcomes, pharmacokinetic/pharmacodynamic modeling, pharmacogenomics, cardiovascular and renal adverse drug effects, and nanoparticle formulation of drugs.

Recent Creative, Scholarly Work and Publications: Murrell, D. E., Kennard, B. C., Bertoni, M. E., Cluck, D. B., Moorman, J. P., Brown, S. D., Wang, K., Duffourc, M. M., & Harirforoosh, S. (2025). An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate. Drugs R D, 25(2), 153-160.; Monfared, A., Murrell, D. E., Shah, D. S., Hoang, M., Brown, S. D., & Harirforoosh, S. (2025). Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood. Toxicol Rep, 15, 102093.; Murrell, D. E., & Harirforoosh, S. (2025). Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Remimazolam. Eur J Drug Metab Pharmacokinet, 50(6), 449-460.; Fankhouser, R. W., Murrell, D. E., Anane, Y. Y., Hurley, D. L., Mamudu, H. M., & Harirforoosh, S. (2022). Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers. Drug Metab Pers Ther, 37(4), 375-382.; Omoike, O. E., Paul, T. K., Ridner, S. L., Awasthi, M., Harirforoosh, S., & Mamudu, H. M. (2020). Association between smoking status and homocysteine levels and possible effect modification by cholesterol and oestradiol. Biomarkers, 25(2), 126-130.; Thigpen, J. C., Odle, B. L., & Harirforoosh, S. (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. Eur J Drug Metab Pharmacokinet, 44(5), 591-609.; Pond, B. B., Brown, S. D., Stewart, D. W., Roane, D. S., & Harirforoosh, S. (2019). Faculty Applicants' Attempt to Inflate CVs Using Predatory Journals. Am J Pharm Educ, 83(1), 7210.; Murrell, D. E., Cluck, D. B., Moorman, J. P., Brown, S. D., Wang, K. S., Duffourc, M. M., & Harirforoosh, S. (2019). HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study. Clin Drug Investig, 39(3), 285-299.; Salwan, A. J., Hagemeier, N. E., & Harirforoosh, S. (2018). Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters? Clin Drug Investig, 38(7), 573-577.; Chen, Y., Xu, C., Harirforoosh, S., Luo, X., & Wang, K. S. (2018). Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol. J Psychiatr Res, 96, 65-72.; Mamudu, H. M., Subedi, P., Paul, T., Alamin, A. E., Alamian, A., Wang, L., Stewart, D., Jones, A., Harirforoosh, S., Blackwell, G., & Budoff, M. (2018). The associated risk factors for coronary artery calcium in asymptomatic individuals with and without diabetes in rural Central Appalachia. J Diabetes Complications, 32(10), 900-905.

Sam Harirforoosh

Biography

Recent Creative, Scholarly Work and Publications

Faculty Directories by School or College